- Home
- MGTX vs AQST Comparison
MGTX vs AQST Comparison
Compare MGTX & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGTX | AQST |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.9M | 809.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | MGTX | AQST |
|---|---|---|
| Price | $8.57 | $6.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $23.83 | $10.00 |
| AVG Volume (30 Days) | 706.5K | ★ 2.8M |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $27,417,000.00 | ★ $43,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $619.95 | $51.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 96.83 | N/A |
| 52 Week Low | $4.55 | $2.12 |
| 52 Week High | $9.73 | $7.55 |
Technical Indicators
Market Signals| Indicator | MGTX | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 58.50 |
| Support Level | $7.60 | $5.90 |
| Resistance Level | $8.34 | $6.34 |
| Average True Range (ATR) | 0.51 | 0.36 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 91.81 | 94.46 |
Price Performance
Historical ComparisonAbout MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.